新一代心肌肌球蛋白抑制剂——aficamten

A new generation cardiac myosin inhibitor:aficamten

aficamten是新一代心肌肌球蛋白抑制剂,通过减少每个心动周期中活性肌球蛋白产力横桥的数量,抑制与肥厚型心肌病相关的心肌过度收缩。FDA和国家药品监督管理局已经分别授予aficamten用于治疗症状性梗阻性肥厚型心肌病的突破性治疗药物认定。本文将对aficamten的基本信息、作用机制、临床前研究及临床研究等作一概述。

Aficamten is a new generation cardiac myosin inhibitor.That inhibits myocardial overcontraction associated with hypertrophic cardiomyopathy by decreasing the amount of active myosin force-producing cross-bridges in each cardiac cycle.Both the FDA and the China National Drug Administration have granted aficamten the designation of a breakthrough therapeutic drug for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.The article provides an overview of the basic information,mechanisms of action,preclinical studies,and clinical studies aficamten.